Gene therapy for murine mucopolysaccharidosis type VII

Neuromuscular Disorders

Volumn 7, Issue 5, 1997, Pages 352-360

  Sands, Mark S ^a   Wolfe, John H ^b   Birkenmeier, Edward H ^c   Barker, Jane E ^c   Vogler, Carole ^d   Sly, William S ^d   Okuyama, Torayuki ^a,e   Freeman, Brian ^a   Nicholes, Andrew ^a   Muzyczka, Nicholas ^f   Chang, Patricia L ^g   Axelrod, Helena R ^h  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PENNSYLVANIA SCHOOL OF VETERINARY MEDICINE   (United States)

^c JACKSON LABORATORY   (United States)

^d SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e NATIONAL RESEARCH INSTITUTE FOR CHILD HEALTH AND DEVELOPMENT   (Japan)

^f UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^g MCMASTER UNIVERSITY   (Canada)

^h Transcell Technologies Inc   (United States)

Author keywords

Gene therapy; Mucopolysaccharidosis type VII; Retroviral vector

Indexed keywords

BETA GLUCURONIDASE; GLYCOSAMINOGLYCAN; LYSOSOME ENZYME; VIRUS VECTOR;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ENZYME DEFICIENCY; EYE; GENE THERAPY; GENE TRANSFER; LIVER; LYSOSOME STORAGE DISEASE; MOUSE; MUCOPOLYSACCHARIDOSIS TYPE 7; NONHUMAN; PRIORITY JOURNAL; RETROVIRUS; SPLEEN;

ADENOVIRIDAE; ANIMALS; BONE MARROW TRANSPLANTATION; DISEASE MODELS, ANIMAL; GENE THERAPY; GENETIC VECTORS; GLUCURONIDASE; HEMATOPOIESIS; MICE; MUCOPOLYSACCHARIDOSIS VII; RODENT DISEASES;

EID: 17544392423     PISSN: 09608966     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-8966(97)00061-8     Document Type: Article

References (69)

1. Neufeld EF, Muenzer J. The mucopolysaccharidoses. In: Scriver C, Beudet A, Sly W, Valle D, eds. The Metabolic and Molecular Basis of Inherited Diseases. New York: McGraw-Hill, 1995;2465-2494.
2. Sly WS, Quinton BA, McAlister WH, Rimoin DL. β-Glucuronidase deficiency: report of clinical, radiologic, and biochemical features of a new mucopolysaccharidosis. Pediatrics 1973;82:249-257.
3. Haskins ME, Desnick RJ, Diferrante N, Jezyk PF, Patterson DF. β-Glucuronidase deficiency in a dog: a model of human mucopolysaccharidosis VII. Pediatr Res 1984;18:980-984.
4. Birkenmeier EH, Davisson MT, Beamer WG, et al. Murine mucopolysaccharidosis type VII: characterization of a mouse with β-glucuronidase deficiency. J Clin Invest 1989;83:1258-1266.
5. Vogler C, Birkenmeier EH, Sly WS, et al. A murine model of mucopolysaccharidosis type VII: gross and microscopic findings in β-glucuronidase-deficient mice. Am J Pathol 1990;136:207-217.
6. Sands MS, Birkenmeier EH. A single-base-pair deletion in the β-glucuronidase gene accounts for the phenotype of murine mucopolysaccharidosis type VII. Proc Natl Acad Sci USA 1993;90:6567-6571.
7. Hobbs JR. Correction of 34 genetic diseases by displacement bone marrow transplantation. Plasma Ther Transfus Technol 1985;6:221-246.
8. Whitley CB, Belani KG, Chang PN, et al. Long-term outcome of Hurler Syndrome following bone marrow transplantation. Am J Med Genet 1993;46:209-218.
9. Birkenmeier EH. Correction of murine mucopolysaccharidosis type VII (MPS VII) by bone marrow transplantation and gene transfer therapy. Hum Gene Ther 1991;2:113.
10. Wolfe JH, Sands MS. Murine mucopolysaccharidodid type VII: a model for somatic gene therapy of the central nervous system. In: Lowenstein P, Enquist L, eds. Gene Transfer into Neurones, Towards Gene Therapy of Neurological Disorders. Chichester: Wiley, 1996;263-274.
11. Birkenmeier EH, Barker JE, Vogler CA, et al. Increased life span and correction of the metabolic defects in murine mucopolysaccharidosis type VII after syngeneic bone marrow transplantation. Blood 1991;11:3081-3092.
12. Poorthuis BJHM, Romme AE, Willemsen R, Wagemaker G. Bone marrow has a significant effect on enzyme levels and storage of glycosaminoglycans in tissues and in isolated hepatocytes of mucopolysaccharidosis type VII mice. Pediatr Res 1994;36:187-193.
13. Sands MS, Barker JE, Vogler CA, et al. Treatment of murine mucopolysaccharidosis type VII by syngeneic bone marrow transplantation in neonates. Lab Invest 1993;68:676-686.
14. Berry CL, Vogler C, Galvin NJ, Birkenmeier EH, Sly WS. Pathology of the ear in murine mucopolysaccharidosis type VII: morphologic correlates of hearing loss. Lab Invest 1994;71:438-445.
15. mps mice with mucopolysaccharidosis (abstract). Association for Research in Otolaryngology, Mid-Winter Meeting, St. Petersburg, FL, 1992.
16. Sands MS, Erway LC, Vogler C, Sly WS, Birkenmeier EH. Syngeneic bone marrow transplantation reduces the hearing loss associated with murine mucopolysaccharidosis type VII. Blood 1995;86:2033-2040.
17. Bastedo L, Sands MS, Lambert DT, Pisa MA, Birkenmeier EH, Chang PL. Behavioural consequences of bone marrow transplantation in the treatment of murine mucopolysaccharidosis type VII. J Clin Invest 1994;94:1180-1186.
18. Gilboa E, Eglitis MA, Kantoff PW, Anderson WF. Transfer and expression of cloned genes using retroviral vectors. BioTechniques 1986;4:504-512.
19. Wolfe JH, Schuchman EH, Stramm LE, et al. Restoration of normal lysosomal function in mucopolysaccharidosis type VII cells by retroviral vector-mediated gene transfer. Proc Natl Acad Sci USA 1990;87:2877-2881.
20. Smith BF, Hoffman RK, Giger U, Wolfe JH. Genes transferred by retroviral vectors into normal and mutant myoblasts in primary culture are expressed in myotubes. Mol Cell Biol 1990;10:3268-3271.
21. Barker JE, McFarland EC. A method to enrich mouse hematopoietic stem cells. Blood 1983;62:827-831.
22. Barker JE, Wolfe JH, Rowe LB, Birkenmeier EH. Advantages of gradient vs. 5-fluorouracil enrichment of stem cells for retroviral-mediated gene transfer. Exp Hematol 1993;21:47-54.
23. Wolfe JH, Sands MS, Barker JE, et al. Reversal of pathology in murine mucopolysaccharidosis type VII by somatic cell gene transfer. Nature 1992;360:749-753.
24. Marechal V, Naffakh N, Danos O, Heard JM. Disappearance of lysosomal storage in spleen and liver of mucopolysaccharidosis type VII mice after transplantation of genetically modified bone marrow cells. Blood 1993;82:1358-1365.
25. Neufeld EF. Lysosomal storage diseases. Annu Rev Biochem 1991;60:257-280.
26. Achord DT, Brot FE, Bell CE, Sly WS. Human β-glucuronidase: in vivo clearance and in vitro uptake by a glycoprotein recognition system on reticuloendothelial cells. Cell 1978;15:269-278.
27. Gabel CA, Goldberg DE, Kornfeld S. Identification and characterization of cells deficient in the mannose 6-phosphate receptor: evidence for an alternate pathway for lysosomal targeting. Proc Natl Acad Sci USA 1983;80:775-779.
28. Beutler E, Kay A, Saven A, et al. Enzyme replacement therapy for Gaucher disease. Blood 1991;78:1183-1189.
29. Barton NW, Brady RO, Dambrosia JM, et al. Replacement therapy for inherited enzyme deficiency - macrophage-targeted glucocerebrosidase for Gaucher's disease. N Engl J Med 1991;324:1464-1470.
30. Shull RM, Kakkis ED, McEntee MF, Kania SA, Jonas AJ, Neufeld EF. Enzyme replacement in a canine model of Hurler syndrome. Proc Natl Acad Sci USA 1994;91:12937-12941.
31. Vogler C, Sands MS, Higgins A, et al. Enzyme replacement with recombinant β-glucuronidase in the newborn mucopolysaccharidosis type VII mouse. Pediatr Res 1993;34:837-840.
32. Sands MS, Vogler C, Kyle JW, et al. Enzyme replacement therapy for murine mucopolysaccharidosis type VII. J Clin Invest 1994;93:2324-2331.
33. Moullier P, Marechal V, Danos O, Heard JM. Continuous systemic secretion of a lysosomal enzyme by genetically modified mouse skin fibroblasts. Transplantation 1993;56:427-432.
34. Moullier P, Bohl D, Heard JM, Danos O. Correction of lysosomal storage in the liver and spleen of MPS VII mice by implantation of genetically modified skin fibroblasts. Nat Genet 1993;4:154-159.
35. Miller AD. Human gene therapy comes of age. Nature 1992;357:455-460.
36. Roemer K, Friedmann T. Concepts and strategies for human gene therapy. Eur J Biochem 1992;208:211-225.
37. Rosenfeld MA, Siegfried W, Yoshimura K, et al. Adenovirus-mediated transfer of a recombinant alpha-1-antitrypsin gene to the lung epithelium in vivo. Science 1991;252:431-434.
38. Yang Y, Nunes FA, Berencsi K, Furth EE, Gonczol E, Wilson JM. Cellular immunity to viral antigens limits El-deleted adenoviruses for gene therapy. Proc Natl Acad Sci USA 1994;91:4407-4411.
39. Davidson BL, Allen ED, Kozarski KF, Wilson JM, Roessler BJ. A model for in vivo gene transfer into the central nervous system using an adenoviral vector. Nat Genet 1993;3:219-223.
40. Akli S, Cailland C, Vigne E, et al. Transfer of a foreign gene onto the brain using adenovirus vectors. Nat Genet 1993;3:224-228.
41. Stramm LE, Haskins ME, Aguirre GD. Retinal pigment epithelial glycosaminoglycan metabolism: intracellular versus extracellular pathways. In vitro studies in normal and diseased cells. Invest Ophthalmol Vis Sci 1989;30:2118-2130.
42. Li T, Davidson BL. Phenotypic correction in retinal pigment epithelium in murine mucopolysaccharidosis type VII by adenovirus-mediated gene transfer. Proc Natl Acad Sci USA 1995;92:7700-7704.
43. Challita PM, Kohn DB. Lack of expression from a retroviral vector after transduction of murine hematopoietic stem cells is associated with methylation in vivo. Proc Natl Acad Sci USA 1994;91:2567-2571.
44. Yu SF, Von Ruden T, Kantoff PW, et al. Self-inactivating retroviral vectors designed for transfer of whole genes into mammalian cells. Proc Natl Acad Sci USA 1986;83:3194-3198.
45. Apperly JF, Luskey BD, Williams DA. Retroviral gene transfer of human adenosine deaminase in murine hematopoietic cells: effect of selectable marker sequences on long term expression. Blood 1991;78:310-317.
46. Hantzopoulos PA, Sullenger BA, Ungers G, Gilboa E. Improved gene expression upon transfer of the adenosine deaminase minigene outside the transcriptional unit of a retroviral vector. Proc Natl Acad Sci USA 1989;86:3519-3523.
47. Wolfe JH, Kyle JW, Sands MS, Sly WS, Markowitz DG, Parente MK. High level expression and export of β-glucuronidase from murine mucopolysaccharidosis VII cells corrected by a double-copy retrovirus vector. Gene Ther 1995;2:70-78.
48. Challita PM, Skelton D, El-Khoueiry A, Yu XJ, Weinberg K, Kohn DB. Multiple modifications in cis elements of the long terminal repeat of retroviral vectors leads to increased expression and decreased methylation in embryonic carcinoma cells. J Virol 1995;69:748-755.
49. Dranoff G, Jaffee E, Lazenby A, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 1993;90:3539-3543.
50. Spangrude GJ, Smith L, Uchida N, et al. Mouse hematopoietic stem cells. Blood 1991; 78:1395-1402.
51. Ogawa M. Differentiation and proliferation of hematopoietic stem cells. Blood 1993;81:2844-2853.
52. Metcalf D. Hematopoietic regulators: redundancy or subtlety? Blood 1993;82:3515-3523.
53. Chang PL, Shen N, Westcott AJ. Delivery of recombinant gene products with microencapsulated cells in vivo. Hum Gene Ther 1993;4:433-440.
54. Al-Hendy A, Hortelano G, Tannenbaum GS, Chang PL. Correction of the growth defect in dwarf mice with non-autologous microencapsulated myoblasts: an alternate approach to somatic gene therapy. Hum Gene Ther 1995;6:165-175.
55. Grubb JH, Kyle JW, Cody LB, Sly WS. Large scale purification of phosphorylated recombinant human β-glucuronidase from overexpressing mouse L cells (abstract). American Society of Biochemistry and Molecular Biology, 1993.
56. Chang PL, Al-Hendy A, Hortelano G, et al. Micro-encapsulated recombinant cells: an alternate approach to gene therapy (abstract). Bioartificial Organs - Science and Technology. Nashville, TN, 1996.
57. Walter J, You Q, Hagstrom JN, Sands MS, High KA. Successful expression of human factor IX following repeat administration of an adenoviral vector in mice. Proc Natl Acad Sci USA 1996;93:3056-3061.
58. Hermonat PL, Muzyczka N. Use of adeno-associated virus as a mammalian DNA cloning vector: transduction of neomycin resistance into mammalian tissue culture cells. Proc Natl Acad Sci USA 1984;81:6466-6470.
59. Berns KI. Parvovirus replication. Microbiol Rev 1990;54:316-329.
60. Muzyczka N. Adeno-associated virus (AAV) vectors: will they work? J Clin Invest 1994;94:1351.
61. Kaplitt MG, Leone P, Samulski RJ, et al. Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain. Nat Genet 1994;8:148-154.
62. Walsh CE, Nienhuis AW, Samulski RJ, et al. Phenotypic correction of Fanconi anemia in human hematopoietic cells with a recombinant adeno-associated virus vector. J Clin Invest 1994;94:1440-1448.
63. Miller JL, Donahue RE, Sellers SE, Samulski RJ, Young NS, Nienhuis AW. Recombinant adeno-associated virus (rAAV)-me-diated expression of a human β-globin gene in human progenitor-derived erythroid cells. Proc Natl Acad Sci USA 1994;91:10183-10187.
64. Goodman S, Xiao X, Donahue RE, et al. Recombinant adeno-associated virus-mediated gene transfer into hematopoietic progenitor cells. Blood 1994;84:1492-1500.
65. Muro-Cacho CA, Samulski RJ, Kaplan D. Gene transfer in human lymphocytes using a vector based on adeno-associated virus. J Immunother 1992;11:231-237.
66. Zhu N, Liggitt D, Liu Y, Debs R. Systemic gene expression after intravenous DNA delivery into adult mice. Science 1993;261:209-211.
67. Thierry AR, Lunardi-Iskandar Y, Bryant JL, Rabinovich P, Gallo RC, Mahan LC. Systemic gene therapy: biodistribution and long-term expression of a transgene in mice. Proc Natl Acad Sci USA 1995;92:9742-9746.
68. Tsukamoto M, Ochiya T, Yoshida S, Sugimura T, Terada M. Gene transfer and expression in progeny after intravenous DNA injection into pregnant mice. Nat Genet 1995;9:243-248.
69. Walker S, Sofia MJ, Kakarla R, et al. Cationic facial amphiphiles: a promising class of transfection agents. Proc Natl Acad Sci USA 1996;93:1585-1590.